The Supreme Court will take a close look at payments from brand-name drug makers to manufacturers of generic equivalents to keep the no-name products off the market at an estimated cost of $3.5 billion a year to consumers. The justices said Friday they will consider competing appeals court decisions about whether the practice known as reverse payments or ‘‘pay for delay’’ illegally reduces competition by delaying the sale of substantially cheaper generic drugs.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help